Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | HAT1 | O14929 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415984 | 1.00 | MAOB (0.44) | MAOBPARP10MAOAHAT1EP300 | |
| SCHEMBL4415983 | 1.00 | MAOB (0.44) | MAOBPARP10MAOAHAT1EP300 | |
| SCHEMBL4420911 | 0.89 | MAOB (0.42) | MAOBPARP10MAOASCN9A | |
| SCHEMBL4420908 | 0.89 | MAOB (0.42) | MAOBPARP10MAOASCN9A | |
| SCHEMBL4418640 | 0.88 | GPR34 (0.52) | MAOBMAOAHAT1EP300SCN9A | |
| SCHEMBL4418038 | 0.88 | GPR34 (0.52) | MAOBMAOAHAT1EP300SCN9A | |
| SCHEMBL4418033 | 0.88 | GPR34 (0.52) | MAOBMAOAHAT1EP300SCN9A | |
| SCHEMBL4417634 | 0.87 | MAOB (0.52) | MAOBPARP10MAOASCN9A | |
| SCHEMBL4425619 | 0.87 | MAOB (0.52) | MAOBPARP10MAOASCN9A | |
| SCHEMBL4417632 | 0.87 | MAOB (0.52) | MAOBPARP10MAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501804-B1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-6818774-B2 | 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | MAOB, MAOA, BACE2 | MAOB 1/4885PARP10 980/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.